ClinicalTrials.gg
CompletedNCT00590590Updated Mar 2, 2012Results posted

Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort

A Phase 2 interventional study of Lidocaine/Diphenhydramine and lidocaine in Vulvodynia, sponsored by Lumara Health, Inc.. Completed at 48 sites in 2 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2012-03-02.

Sponsored by Lumara Health, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Vulvodynia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Vulvodynia · United States.

Enrollment
6th of 36
105 · median 45
Started
2007
with 2 others
Phase 2
10 of 47
3 open now
Registered
6th of 47
by date

Among the 47 studies in Vulvodynia with a site in United States, this one is the 6th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2007, is one of 10 in phase 2, and was the 6th registered.

Vulvodynia

117 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.

Browse Vulvodynia studies →

Open to participants now

8 of the 47 studies in Vulvodynia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Vulvodynia studies recruiting now, 8 (62%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Vulvodynia with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of two vaginal products compared with that of placebo to determine if the two products are better than placebo in the relief of vaginal discomfort.

03

Conditions studied

  • Vulvodynia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have sought doctor's care for this condition.
  • Patients must be having menstrual cycles.

Exclusion criteria

Exclusion Criteria:

  • Patients must not have any vaginal infections.
  • Patients must not be pregnant or nursing.
  • Must not be receiving any other medicinal therapies or any medications that would interfere with the outcome of the study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Placebo comparator
    3 (Placebo)

    Drug: placebo

  • Experimental
    1 (Lidocaine)

    Drug: lidocaine

  • Experimental
    2 (Lidocaine/Diphenhydramine)

    Drug: Lidocaine/Diphenhydramine

Interventions

  • DrugLidocaine/Diphenhydramine

    Drug pages: Lidocaine · Diphenhydramine

    semi solid, twice weekly, 4 months

  • semi solid, twice weekly for 4 months

  • Drugplacebo

    semi solid, twice weekly for 4 months

06

What researchers measure

Primary outcomes

  1. Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks)

    The MDSS consists of a participant rating of their dyspareunia (painful sexual intercourse) on a 0- to 3-point scale. Each numerical value on the scale coincides with a level of pain experienced during sexual intercourse; 0 = no dyspareunia (no pain with intercourse) and 3 = completely prevents intercourse

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks)

    0-3 scale with 0=no dyspareunia and 3= completely prevents intercourse

    Time frame: Baseline -12 Weeks

  2. Change From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort]

    Time frame: 12 Weeks

  3. Change From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain]

    Time frame: 12 weeks

  4. Change From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be]

    Time frame: 12 Weeks

  5. Change From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe]

    Time frame: 12 Weeks

07

Results

Posted Feb 9, 2011
Limitations and caveats
The study was discontinued following enrollment of 106 of the planned 140 participants due to slow recruitment.

Participant flow

Participants were recruited from 31 physician offices in the US and Canada between 04Sep2007 to 18Mar2009.

Participant flow — Overall Study
MilestoneLidocaine/Diphenhydramine (Combination)LidocainePlacebo
Started393927
Completed323321
Not completed766
Withdrew: Lack of efficacy120
Withdrew: Adverse event100
Withdrew: Protocol violation002
Withdrew: Lost to follow-up412
Withdrew: Withdrawal by subject011
Withdrew: Did not complete due to study closure111
Withdrew: Did not complete study010

Outcome measures

PrimaryMean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks)

The MDSS consists of a participant rating of their dyspareunia (painful sexual intercourse) on a 0- to 3-point scale. Each numerical value on the scale coincides with a level of pain experienced during sexual intercourse; 0 = no dyspareunia (no pain with intercourse) and 3 = completely prevents intercourse

Time frame:
12 weeks
Reported as:
Mean · scores on a scale
Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks)
scores on a scaleLidocaine/Diphenhydramine (Combination)LidocainePlacebo
Mean Marinoff Dyspareunia Scale Score (MDSS) at End of Treatment (12 Weeks)1.8 ± 0.121.8 ± 0.121.7 ± 0.14
Statistical analysis
  • Lidocaine/Diphenhydramine (Combination) vs Lidocaine · Mean difference (final values): 0
  • Lidocaine/Diphenhydramine (Combination) vs Placebo · Mean difference (final values): 0.1
  • Lidocaine vs Placebo · Mean difference (final values): 0.1
SecondaryChange From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks)

0-3 scale with 0=no dyspareunia and 3= completely prevents intercourse

Time frame:
Baseline -12 Weeks
Reported as:
Mean · Score
Change From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks)
ScoreLidocaine/Diphenhydramine (Combination)LidocainePlacebo
Change From Baseline in Marinoff Dyspareunia Scale Score at End of Treatment (12 Weeks)-0.6 ± 0.15-0.4 ± 0.13-0.7 ± 0.15
Statistical analysis
  • Lidocaine/Diphenhydramine (Combination) vs Lidocaine · Mean difference (final values): -0.2
  • Lidocaine/Diphenhydramine (Combination) vs Placebo · Mean difference (final values): 0.1
  • Lidocaine vs Placebo · Mean difference (final values): 0.3
SecondaryChange From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort]
Time frame:
12 Weeks
Reported as:
Mean · Score
Change From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort]
ScoreLidocaine/Diphenhydramine (Combination)LidocainePlacebo
Change From Baseline in Overall Vulvar Vestibulitis Syndrome (VVS)-Related Discomfort Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Discomfort and 100 = Most Severe Discomfort]-9.9 ± 3.48-3.8 ± 4.46-14.6 ± 4.56
Statistical analysis
  • Lidocaine/Diphenhydramine (Combination) vs Lidocaine · Mean difference (final values): -6.1
  • Lidocaine/Diphenhydramine (Combination) vs Placebo · Mean difference (final values): 4.7
  • Lidocaine vs Placebo · Mean difference (final values): 10.8
SecondaryChange From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain]
Time frame:
12 weeks
Reported as:
Mean · Score
Change From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain]
ScoreLidocaine/Diphenhydramine (Combination)LidocainePlacebo
Change From Baseline in Overall Intercourse-Related Pain Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Pain and 100 = Most Severe Pain]-10.3 ± 5.71-19.6 ± 4.42-19.3 ± 6.55
Statistical analysis
  • Lidocaine/Diphenhydramine (Combination) vs Lidocaine · Mean difference (final values): 9.3
  • Lidocaine/Diphenhydramine (Combination) vs Placebo · Mean difference (final values): 9
  • Lidocaine vs Placebo · Mean difference (final values): -0.3
SecondaryChange From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be]
Time frame:
12 Weeks
Reported as:
Mean · Score
Change From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be]
ScoreLidocaine/Diphenhydramine (Combination)LidocainePlacebo
Change From Baseline in Overall Vulvar Vestibulitis Symptoms Visual Analog Scale (VAS) Score at End of Treatment (12 Weeks) [0 = No Symptoms and 100 = As Bad as They Can be]-10.4 ± 4.31-5.3 ± 4.47-16.3 ± 4.22
Statistical analysis
  • Lidocaine/Diphenhydramine (Combination) vs Lidocaine · Mean difference (final values): -5.1
  • Lidocaine/Diphenhydramine (Combination) vs Placebo · Mean difference (final values): 5.9
  • Lidocaine vs Placebo · Mean difference (final values): 11
SecondaryChange From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe]
Time frame:
12 Weeks
Reported as:
Mean · Score
Change From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe]
ScoreLidocaine/Diphenhydramine (Combination)LidocainePlacebo
Change From Baseline in Tenderness (on a 0- to 3-point Scale) on Palpation at End of Treatment (12 Weeks) [Scale Rates the Severity of Pain; 0 =Absent and 3 = Severe]-3.0 ± 0.70-1.7 ± 0.67-2.4 ± 0.75
Statistical analysis
  • Lidocaine/Diphenhydramine (Combination) vs Lidocaine · Mean difference (final values): -1.3
  • Lidocaine/Diphenhydramine (Combination) vs Placebo · Mean difference (final values): -0.6
  • Lidocaine vs Placebo · Mean difference (final values): 0.7

Adverse events

Collected over 16 weeks for each subject. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lidocaine/Diphenhydramine (Combination)—0/39 (0%)30/39 (76.9%)
Lidocaine—0/39 (0%)30/39 (76.9%)
Placebo—0/27 (0%)23/27 (85.2%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventLidocaine/Diphenhydramine (Combination)LidocainePlacebo
NasopharyngitisInfections and infestations7/394/396/27
HeadacheNervous system disorders8/395/393/27
DysmenorrhoeaReproductive system and breast disorders3/394/394/27
Vulvovaginal burning sensationReproductive system and breast disorders4/393/394/27
Vulvovaginal pruritusReproductive system and breast disorders1/395/391/27
Fungal infectionInfections and infestations3/394/392/27
Vaginal candidiasisInfections and infestations2/394/392/27
Vulvovaginal discomfortReproductive system and breast disorders3/394/391/27
Urinary tract infectionInfections and infestations1/393/391/27
Vaginal DischargeReproductive system and breast disorders3/392/391/27

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lidocaine/Diphenhydramine (Combination)LidocainePlaceboTotal
<=18 years0000
Between 18 and 65 years393927105
>=65 years0000
Age Continuous
Age Continuous(years)Lidocaine/Diphenhydramine (Combination)LidocainePlaceboTotal
Mean30 ± 7.432 ± 9.032 ± 9.531 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Lidocaine/Diphenhydramine (Combination)LidocainePlaceboTotal
Female393927105
Male0000
Region of Enrollment
Region of Enrollment(participants)Lidocaine/Diphenhydramine (Combination)LidocainePlaceboTotal
United States363925100
Canada3025
08

Study locations

48 sites
  • Montgomery Women's Health Associates, P.C.
    Montgomery, Alabama 36116, United States
  • Star W. Research
    Chandler, Arizona 85225, United States
  • Precision Trials LLC
    Phoenix, Arizona 85032, United States
  • Searcy Medical Center
    Searcy, Arkansas 72143, United States
  • Universal Biopharma Research Institute, Inc.
    Dinuba, California 93618, United States
  • San Diego Clinical Research Center
    San Diego, California 92103, United States
  • Red Rocks OB/GYN
    Lakewood, Colorado 80228, United States
  • Taylor Associates/Gynecology
    Farmington, Connecticut, United States
  • Women's Medical Research Group, LLC
    Clearwater, Florida 33759, United States
  • Clinical Research of Tampa Bay
    Hudson, Florida 34667, United States
  • Innovative Research of W. Florida
    Largo, Florida 33770, United States
  • Women's Health Care Specialists, PC
    Paw Paw, Florida 49079, United States
  • Tampa Bay Women's Healthcare Alliance, LLP
    Tampa, Florida 33607, United States
  • Comprehensive Clinical Trials, LLC
    West Palm Beach, Florida 33409, United States
  • Atlanta Women's Research Institute, Inc.
    Atlanta, Georgia 30342, United States
  • Atlanta North Gynecology, PC
    Roswell, Georgia 30075, United States
  • Womans Clinic
    Boise, Idaho 83712, United States
  • Rosemark Women Care Specialists
    Idaho Falls, Idaho 83404, United States
  • Women's Health Practice, LLC
    Champaign, Illinois 61820, United States
  • Northern Indiana Womens Health Research
    South Bend, Indiana 46601, United States
  • Female Pelvic Medicine and Urogynecology
    Grand Rapids, Michigan 49506, United States
  • Boro Park ObGyn
    Brooklyn, New York 11219, United States
  • Eastern Carolina Womens Center
    New Bern, North Carolina 28562, United States
  • Lyndhurst Clinical Research
    Winston Salem, North Carolina 27103, United States
  • Winston-Salem Woman Care, PA
    Winston-Salem, North Carolina 27103, United States
  • Holzer Clinic
    Gallipolis, Ohio 45631, United States
  • HWC Women's Research Center
    Miamisburg, Ohio 45342, United States
  • Advanced Clinical Research
    Medford, Oregon 97504, United States
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18105, United States
  • Advanced Clinical Concepts
    West Reading, Pennsylvania 19611, United States
  • Hillcrest Clinical Research, LLC
    Simpsonville, South Carolina 29681, United States
  • Southeastern Clinical Research
    Chattanooga, Tennessee 37403, United States
  • The Jackson Clinic, PA
    Jackson, Tennessee 38305, United States
  • Women's Care Center, PLC
    Memphis, Tennessee 38119, United States
  • Gynecology and Obstetrics, P.C.
    Memphis, Tennessee 38120, United States
  • Professional Quality Research/Women Partners
    Austin, Texas 78705, United States
  • Advanced Research Associates
    Corpus Christi, Texas 78414, United States
  • Woman's Hospital of Texas
    Houston, Texas 77054, United States
  • Bexar Clinical Trials
    Irving, Texas 75061, United States
  • Salt Lake Research
    Salt Lake City, Utah 84107, United States
  • Salt Lake Women's Center
    Sandy, Utah 84070, United States
  • Gain Medical Centre
    Coquitlam, British Columbia V3K 3P4, Canada
  • Stephen Kaye, MD
    North Vancouver, British Columbia V7M 2H5, Canada
  • Southern Healthcare Centre
    White Rock, British Columbia V4B 5C9, Canada
  • Common Wealth Medical Clinic
    Mt. Pearl, Newfoundland and Labrador A1N 1W7, Canada
  • The Ottawa Hospital-Soundcare Medical Centre
    Ottawa, Ontario K1V 0Y3, Canada
  • Royal Health Care Centre
    Toronto, Ontario M5H 3P5, Canada
  • Windsor Metropolitan Hospital
    Windsor, Ontario N8X 3V6, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jun 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2007
First posted
Jan 10, 2008
Start
Oct 2007
Primary completionActual
Jun 2009
CompletionActual
Jul 2009
Results first posted
Feb 9, 2011
Last update
Mar 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00590590
Lead sponsor
Lumara Health, Inc.
Responsible party
Sponsor
First posted
Jan 10, 2008
Start date
Oct 2007
Primary completion
Jun 2009
Completion
Jul 2009
Results posted
Feb 9, 2011
Last update
Mar 2, 2012

Study contacts

Jim Joffrion
study director · Lumara Health, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Diphenhydramine

Start the discussion